Alere Determine-tuberculosis lipoarabinomannan positivity in disseminated non-tuberculous mycobacteria: An illustrative case series

Southern African Journal of HIV Medicine

 
 
Field Value
 
Title Alere Determine-tuberculosis lipoarabinomannan positivity in disseminated non-tuberculous mycobacteria: An illustrative case series
 
Creator Greyling, Riana Meintjes, Graeme Sossen, Bianca
 
Subject Medicine; Infectious Diseases tuberculosis; Lipoarabinomannan; ambulatory; outpatient; point-of-care; urine; HIV; diagnostic
Description Introduction: In outpatients, the World Health Organization recommends that the urine Alere Determine-tuberculosis lipoarabinomannan (AlereLAM) should be used to support the diagnosis of tuberculosis (TB) in people living with HIV (PLHIV) with CD4 counts ≤ 100 cells/µL or with signs of being ‘seriously ill’. There is a risk of a false-positive AlereLAM in disseminated non-tuberculous mycobacterial (NTM) infections and it may be difficult to differentiate a single infection (either Mycobacterium tuberculosis or NTM) from dual infection.Patient presentation: We report three patients, enrolled in an operational study assessing AlereLAM use in an outpatient setting, who had advanced HIV (all CD4 20 cells/µL) and strongly positive (grade 4+) AlereLAM results in whom Mycobacterium avium or kansasii were later cultured from blood or urine and sputum.Management and outcome: Based on positive AlereLAM results, all three were initiated on TB treatment. One died before NTM infection was detected. Two were managed for dual infection (TB and NTM) but died within two years.Conclusion: Tuberculosis remains a leading cause of death and a disproportionate number of these deaths occur in PLHIV. Tuberculous treatment should be initiated based on a positive AlereLAM result, and this should be followed by additional testing to confirm the diagnosis of TB and to obtain drug susceptibility results. In those not responding to TB treatment where the only positive result was an AlereLAM, an alternative or additional diagnosis of NTM infection should be considered, particularly in patients with a very low CD4 count.
 
Publisher AOSIS
 
Contributor N/A
Date 2022-04-04
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Observational Study
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajhivmed.v23i1.1369
 
Source Southern African Journal of HIV Medicine; Vol 23, No 1 (2022); 3 pages 2078-6751 1608-9693
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajhivmed.org.za/index.php/hivmed/article/view/1369/2731 https://sajhivmed.org.za/index.php/hivmed/article/view/1369/2732 https://sajhivmed.org.za/index.php/hivmed/article/view/1369/2733 https://sajhivmed.org.za/index.php/hivmed/article/view/1369/2734
 
Coverage South Africa — —
Rights Copyright (c) 2022 Riana Greyling, Graeme Meintjes, Bianca Sossen https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT